Stocks to Watch

IntelGenx (IGXT) Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)


SAINT LAURENT, Quebec, Nov. 26, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL® 450 mg tablets.

Under the terms of the settlement, Wockhardt has been granted the rights, with effect from January 15, 2018, to be the exclusive marketer and distributor of an authorized generic of Forfivo XL® in the U.S.